Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RARE 3: Tiragolumab + Atezolizumab in Advanced Rare Tumors
NCT05715281Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2023
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab, atezolizumab, sponsored by National Cancer Institute. Started Sep 2023; status: active, not recruiting.
02
Drugs
tiragolumabatezolizumab
Beyond the preview
Go deeper on NCT05715281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715281.